Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
10:31am, Thursday, 19'th Dec 2024
Vertex Pharmaceuticals (VRTX) shares sank Thursday morning after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
Cramer's Stop Trading: Vertex Pharmaceuticals
10:17am, Thursday, 19'th Dec 2024
CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
07:09am, Thursday, 19'th Dec 2024
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
06:00am, Thursday, 19'th Dec 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal
KING OF PRUSSIA, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, has been named a Leader in three
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
11:56am, Wednesday, 11'th Dec 2024
I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
01:23pm, Monday, 09'th Dec 2024
Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportuni
Vertex (VERX) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 02'nd Dec 2024
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Vertex (VERX) is a Great Momentum Stock: Should You Buy?
01:00pm, Friday, 29'th Nov 2024
Does Vertex (VERX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vertex, Inc. (VERX) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 27'th Nov 2024
Vertex (VERX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Vertex Stock Worth Buying Despite Its 105% Year-to-Date Rally?
10:01am, Wednesday, 27'th Nov 2024
VERX's impressive financial performance, accelerating cloud transition and strategic positioning make it a strong contender in the tax compliance market.
Vertex Pharma: Why I Am Buying This Dip
10:53am, Monday, 25'th Nov 2024
Vertex Pharmaceuticals reported strong Q3 earnings, yet the stock has pulled back, presenting a buying opportunity. The company's robust pipeline, particularly Suzetrigine for acute pain and CASGEVY g
Vertex Pharmaceuticals initiated with a Buy at Citi
04:12pm, Wednesday, 13'th Nov 2024
Citi initiated coverage of Vertex Pharmaceuticals with a Buy rating and $575 price target. The firm believes Vertex is positioned to remain a leader in the cystic fibrosis, or CF, space, with its curr
Why Vertex (VERX) Might be Well Poised for a Surge
01:26pm, Wednesday, 13'th Nov 2024
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Growth Investors Will Love Vertex (VERX)
01:50pm, Tuesday, 12'th Nov 2024
Vertex (VERX) possesses solid growth attributes, which could help it handily outperform the market.
